Double-stranded nucleotide compound for metabolic diseases and use thereof

A double-stranded nucleotide compound, specifically siRNA, addresses the inadequacies in DGAT-2 expression treatments by effectively inhibiting DGAT-2, providing a genetic engineering solution for metabolic diseases.

HK40135213APending Publication Date: 2026-07-17VISIRNA THERAPEUTICS (SUZHOU) CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
VISIRNA THERAPEUTICS (SUZHOU) CO LTD
Filing Date
2026-06-09
Publication Date
2026-07-17

AI Technical Summary

Technical Problem

Current treatments for metabolic diseases related to diacylglycerol acyltransferase-2 (DGAT-2) expression are inadequate, necessitating a more effective method to inhibit DGAT-2 expression for therapeutic intervention.

Method used

A double-stranded nucleotide compound, specifically small interfering RNA (siRNA), is developed to target and inhibit DGAT-2 expression, providing a genetic engineering approach for drug preparation and treatment.

Benefits of technology

The siRNA effectively inhibits DGAT-2 expression, offering a promising therapeutic strategy for metabolic diseases by targeting the underlying genetic cause.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Relates to the technical field of gene engineering, in particular to small interfering RNA for inhibiting expression of diacylglycerol acyltransferase-2 (DGAT-2) and application of the small interfering RNA to preparation of drugs for treating diseases related to DGAT2 expression.
Need to check novelty before this filing date? Find Prior Art

Description

(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202480034528.2 (22) Application Date 2024.05.24 (66) Domestic Priority Data 202310609515.0 2023.05.26 CN 202410645783.2 2024.05.23 CN (85) PCT International Application Entering National Phase Date 2025.11.24 (86) PCT International Application Application Data PCT / CN2024 / 095285 2024.05.24 (87) PCT International Application Publication Data WO2024 / 245151 ZH 2024.12.05 (71) Applicant Viagene Biotechnology (Suzhou) Co., Ltd. Address 215028 Unit 401, Building 5, Block B, Phase III, Biomedical Industrial Park, No. 99 Jingu Road, Suzhou Industrial Park, Suzhou Area, China (Jiangsu) Pilot Free Trade Zone, Suzhou City, Jiangsu Province (72) Inventors: He Qionger, Wang Mingjie, Zou Xiaoming, Yang Hongkuan (74) Patent Agency: Junhe Law Firm, Beijing 11517 Patent Attorneys: Wu Yu, Zhao Hao (51) Int.Cl. C12N 15 / 113 (2006.01) A61P 1 / 16 (2006.01) A61K 31 / 713 (2006.01) A61K 47 / 54 (2006.01) A61K 31 / 712 (2006.01) A61P 3 / 06 (2006.01) (54) Invention Title: A Double-Stranded Nucleotide Compound for Metabolic Diseases and Its Application (57) Abstract: This invention relates to the field of genetic engineering technology, specifically to a small interfering RNA that inhibits the expression of diacylglycerol acyltransferase-2 (DGAT-2) and its use in the preparation and treatment of drugs for diseases related to DGAT2 expression. CN 121311587 A 2026.01.09 CN 1 21 31 15 87 A